Highlights from the Ratings and Financial Report for Arcus Biosciences Inc. (RCUS) – News Heater
Home  »  Hot Stocks   »  Highlights from the Ratings and Financial Report f...

Highlights from the Ratings and Financial Report for Arcus Biosciences Inc. (RCUS)

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Arcus Biosciences Inc. (NYSE:RCUS) went up by 8.03% from its latest closing price compared to the recent 1-year high of $42.36. The company’s stock price has collected 12.71% of gains in the last five trading sessions. Press Release reported 14 hours ago that Infinity Pharmaceuticals Hosting Webinar on MARIO-3 and MARIO-275 Phase 2 Trials

>> 7 Top Picks for the Post-Pandemic Economy <<

Is It Worth Investing in Arcus Biosciences Inc. (NYSE :RCUS) Right Now?

Plus, the 36-month beta value for RCUS is at 1.15. Opinions of the stock are interesting as 9 analysts out of 10 who provided ratings for Arcus Biosciences Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $54.00. RCUS currently public float of 44.81M and currently shorts hold a 15.11% ratio of that float. Today, the average trading volume of RCUS was 711.11K shares.

RCUS’s Market Performance

RCUS stocks went up by 12.71% for the week, with a monthly jump of 38.81% and a quarterly performance of 0.19%, while its annual performance rate touched 29.60%. The volatility ratio for the week stands at 6.21% while the volatility levels for the past 30 days are set at 5.26% for Arcus Biosciences Inc.. The simple moving average for the period of the last 20 days is 15.79% for RCUS stocks with a simple moving average of 10.10% for the last 200 days.

Analysts’ Opinion of RCUS

Many brokerage firms have already submitted their reports for RCUS stocks, with Berenberg repeating the rating for RCUS by listing it as a “Buy.” The predicted price for RCUS in the upcoming period, according to Berenberg is $50 based on the research report published on November 24th of the previous year 2020.

Cantor Fitzgerald gave a rating of “Overweight” to RCUS, setting the target price at $21 in the report published on April 03rd of the previous year.

RCUS Trading at 20.84% from the 50-Day Moving Average

After a stumble in the market that brought RCUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.43% of loss for the given period.

Volatility was left at 5.26%, however, over the last 30 days, the volatility rate increased by 6.21%, as shares surge +36.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.12% upper at present.

During the last 5 trading sessions, RCUS rose by +12.71%, which changed the moving average for the period of 200-days by +86.43% in comparison to the 20-day moving average, which settled at $28.07. In addition, Arcus Biosciences Inc. saw 23.31% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RCUS starting from Grossman William, who sale 3,891 shares at the price of $23.68 back on Jun 17. After this action, Grossman William now owns 20,723 shares of Arcus Biosciences Inc., valued at $92,139 using the latest closing price.

Jaen Juan C., the President of Arcus Biosciences Inc., sale 2,675 shares at $23.68 during a trade that took place back on Jun 17, which means that Jaen Juan C. is holding 198,286 shares at $63,344 based on the most recent closing price.

Stock Fundamentals for RCUS

Current profitability levels for the company are sitting at:

  • -160.27 for the present operating margin

The net margin for Arcus Biosciences Inc. stands at -158.49. The total capital return value is set at -36.31, while invested capital returns managed to touch -36.06. Equity return is now at value -31.30, with -22.40 for asset returns.

Based on Arcus Biosciences Inc. (RCUS), the company’s capital structure generated 3.61 points at debt to equity in total, while total debt to capital is 3.48. Total debt to assets is 2.34, with long-term debt to equity ratio resting at 3.03. Finally, the long-term debt to capital ratio is 2.93.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 9.18, with the company’s debt to enterprise value settled at 0.03. The receivables turnover for the company is 84.72 and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.05.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam